Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10225)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
CCDC6
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Testicular cancer | ICD-11: 2C80 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
NTERA-2 cells | Embryonal carcinoma | Homo sapiens | CVCL_0034 |
TM4 cells | Normal | Mus musculus | CVCL_4327 | |
MZ-GC-1 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_4U28 | |
MZ-GC-2 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_4U29 | |
Response regulation | Testicular cancers are among the most common malignancies in young males. The loss of CCDC6 was associated with an enhancement of the xCT/SLC7A11 cystine antiporter expression which, by promoting the accumulation of ROS, interfered with the activation of ferroptosis pathway. | |||
Testicular cancer [ICD-11: 2C80]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Coiled-coil domain-containing protein 6 (CCDC6) | Protein coding | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
NTERA-2 cells | Embryonal carcinoma | Homo sapiens | CVCL_0034 |
TM4 cells | Normal | Mus musculus | CVCL_4327 | |
MZ-GC-1 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_4U28 | |
MZ-GC-2 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_4U29 | |
Response regulation | Testicular cancers are among the most common malignancies in young males. The loss of CCDC6 was associated with an enhancement of the xCT/SLC7A11 cystine antiporter expression which, by promoting the accumulation of ROS, interfered with the activation of ferroptosis pathway. | |||